What Are Your Moves Tomorrow, September 18, 2026

{"summary": "Author is bullish on Moderna ahead of its pipeline presentation next Wednesday, citing a cancer drug under approval review and colorectal/skin cancer trial results expected in October or November, with a speculative €1,000 price target.", "reason": "The author provides a specific catalyst (pipeline presentation and trial results) and a directional investment judgment based on those events.", "ideas": [{"symbol": "MRNA", "direction": "long", "thesis": "The author claims Moderna will present its pipeline next Wednesday, including a cancer drug whose approval is under review, and is studying treatments for colorectal and skin cancer with results expected in October or November. The catalyst is the upcoming pipeline presentation and the October/November trial readouts, which the author believes could drive the stock to €1,000 if successful. The main risk is that the trial results or approval may fail, making the €1,000 target highly speculative.", "thesis_short": "Moderna pipeline presentation and cancer trial catalysts", "quote": "Moderna \nwill \npresent \nits \npipeline \nnext \nWednesday \nat \n2:50 \np.m., \nincluding \na \ncancer \ndrug \nwhose \napproval \nis \nunder \nreview. \nIt \nis \ncurrently \nstudying \na \ntreatment \nfor \ncolorectal \nand \nskin \ncancer, \nwith \nresults \nexpected \nin \nOctober \nor \nNovember. \nIf \nsuccessful, \nI \nsee \nthe \nstock \nreaching \n€1,000.", "confidence": 0.7, "sentiment": 0.8, "timeframe": "October or November"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}